3'-O-(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine | 1030372-02-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 3'-O-(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine
• 英文别名: [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[tert-butyl(dimethyl)silyl]oxy-4-fluorooxolan-2-yl]methanol
• CAS: 1030372-02-1
• 化学式: C₁₆H₂₆FN₅O₃Si
• 分子量: 383.498
• InChiKey: LEFBANVCKNZLKN-NDLNZWKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.03
• 重原子数：
  26.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  108.31
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  3'-O-(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine 在 吡啶 、 三甲基氯硅烷 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 二甲基亚砜 为溶剂， 反应 13.0h， 生成 ((3R,4R,5R)-3-((tert-butyldimethylsilyl)oxy)-4-fluoro-5-(6-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)tetrahydrofuran-2,2-diyl)dimethanol
  参考文献：
  名称：

  SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

  摘要：

  本文披露了核苷、核苷酸及其类似物，包括一个或多个核苷、核苷酸及其类似物的药物组合物，以及它们的合成方法。本文还披露了使用核苷、核苷酸和其类似物来改善和/或治疗疾病和/或病况的方法，包括使用核苷、核苷酸和其类似物来治疗副粘病毒和/或正粘病毒感染的方法。

  公开号：

  US20130165400A1
• 作为产物：
  描述：

  阿糖腺苷 在 吡啶 、 二乙胺基三氟化硫 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.33h， 生成 3'-O-(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine
  参考文献：
  名称：

  Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase

  摘要：

  The biosynthesis of pantothenate, the core of coenzyme A (CoA), has been considered an attractive target for the development of antimicrobial agents since this pathway is essential in prokaryotes, but absent in mammals. Pantothenate synthetase, encoded by the gene panC, catalyzes the final condensation of pantoic acid with beta-alanine to afford pantothenate via an intermediate pantoyl adenylate. We describe the synthesis and biochemical characterization of five PanC inhibitors that mimic the intermediate pantoyl adenylate. These inhibitors are competitive inhibitors with respect to pantoic acid and possess submicromolar to micromolar inhibition constants. The observed SAR is rationalized through molecular docking studies based on the reported co-crystal structure of 1a with PanC. Finally, whole cell activity is assessed against wild-type Mtb as well as a PanC knockdown strain where PanC is depleted to less than 5% of wild-type levels. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.017

文献信息

• [EN] NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS<br/>[FR] NOUVEAUX RÉACTIFS À BASE DE PHOSPHORE (V), LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION DANS LA FABRICATION DE COMPOSÉS ORGANOPHOSHOREUX (V) STÉRÉODÉFINIS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019200273A1

  公开（公告）日：2019-10-17

  The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

  本发明涉及新型磷（V）（P(V)）试剂，其制备方法以及利用这种新型试剂制备有机磷（V）化合物的方法。
• [EN] S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS<br/>[FR] POLYMÈRES OLIGONUCLÉOTIDIQUES INHIBANT LE TRANSPORT DE L'ANTIGÈNE S ET MÉTHODES
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2021119325A1

  公开（公告）日：2021-06-17

  Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

  各种实施方式提供了STOPS™聚合物，这些聚合物是S-抗原转运抑制寡核苷酸聚合物，提供了制备它们的方法以及使用它们治疗疾病和症状的方法。在某些实施方式中，STOPS™修饰的寡核苷酸包括至少部分磷硫酸酯化的交替A和C单元序列，具有如本文所述的修饰。通过HBsAg分泌测定确定的STOPS™修饰的寡核苷酸对乙型肝炎的序列无关抗病毒活性，其EC50小于100 nM。
• [EN] SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF<br/>[FR] NUCLÉOSIDES SUBSTITUÉS, NUCLÉOTIDES ET ANALOGUES DE CEUX-CI
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2014209983A1

  公开（公告）日：2014-12-31

  Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.

  本文披露了核苷、核苷酸及其类似物，包括一个或多个核苷、核苷酸及其类似物的药物组合物，以及合成它们的方法。本文还披露了使用核苷、核苷酸及其类似物来改善和/或治疗副粘病毒感染的方法。
• Aminoacyl-tRNA Synthetase Inhibitors as Potent and Synergistic Immunosuppressants
  作者：Pieter Van de Vijver、Tomasz Ostrowski、Brian Sproat、Jozef Goebels、Omer Rutgeerts、Arthur Van Aerschot、Mark Waer、Piet Herdewijn

  DOI：10.1021/jm8000746

  日期：2008.5.1

  The aminoacyl-tRNA synthetase family of enzymes is the target of many antibacterials and inhibitors of eukaryotic hyperproliferation. In screening analogues of 5'-O-(N-L-aminoacyl)-sulfamoyladenosine containing all 20 proteinogenic amino acids, we found these compounds to have potent immunosuppressive activity. Also, we found that combinations of these compounds inhibited the immune response synergistically. Based on these data, analogues with modifications at the aminoacyl and ribose moieties were designed and evaluated, and several of these showed high immunosuppressive potency, with one compound having an IC(50) of 80 nM, when tested in a cellular mixed lymphocyte reaction assay. Apart from showing the potential of aminoacyl-tRNA synthetase inhibitors as immunosuppressants, the current study also provides arguments for careful evaluation of the immunosuppressive activity of developmental antibacterials that target these enzymes.